BioSpace News Archive

Debiopharm and Verity Pharmaceuticals Inc. announced having entered into an exclusive agreement that grants Verity Pharmaceuticals Inc., in the United States of America, the rights to commercialize Trelstar® a hormone therapy for patients living with prostate cancer.

Results will be Presented to Scientific Community at AAD 2020 VMX Virtual Meeting Experience held June 12-14, 2020 online at aad.org

The Seven Bridges Bioinformatics Ecosystem Supports the Critical Turnaround Times for the CareDx AlloSure® 3.0 Workflow

St. Vincent de Paul announced it has launched rapid COVID-19 testing, together with CVS Health, at the nonprofit’s Virginia G. Piper Medical & Dental Clinic for the uninsured.

KromaTiD, Inc. announced the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert tracking assay.

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.

ERYTECH Pharma provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology of eryaspase in second-line acute lymphoblastic leukemia patients.

Hutchison China MediTech Limited announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, its 50:50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMSTM diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix, has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test.

The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company’s investigational dual GIP and GLP-1 receptor agonist.